These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 121847)

  • 21. Histologic responses in sixty multibacillary leprosy patients inoculated with autoclaved Mycobacterium leprae and live BCG.
    Meyers WM; McDougall AC; Fleury RN; Neves R; Reyes O; Binford CH
    Int J Lepr Other Mycobact Dis; 1988 Jun; 56(2):302-9. PubMed ID: 3045226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rosette-forming cells in patients with treated leprosy.
    Dang DT; Pham MH; Hoang TL; Lai VG; Nguyen HH
    Int J Lepr Other Mycobact Dis; 1983 Jun; 51(2):174-8. PubMed ID: 6684644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on search for a promising immunopotentiative substance for treatment of leprosy. III. With special reference to an immunomodulative drug CCA, a BCG vaccine and the significance of an improved rabbit red blood cell rosette formation test.
    Gidoh M; Tsutsumi S
    Nihon Rai Gakkai Zasshi; 1983; 52(3):165-79. PubMed ID: 6678932
    [No Abstract]   [Full Text] [Related]  

  • 24. [Immunomodulator treatment of multibacillary leprosy using extracts of microbial ribosomes].
    Saint-André P; Baquillon G; David M
    Acta Leprol; 1989; 7(1):57-8. PubMed ID: 2483016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to Mycobacterium leprae is associated with defective expression of interleukin 2 receptors and is not reconstituted by interleukin 2.
    Mohagheghpour N; Gelber RH; Larrick JW; Sasaki DT; Brennan PJ; Engleman EG
    J Immunol; 1985 Aug; 135(2):1443-9. PubMed ID: 2989366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transformation from lepromatous to borderline leprosy under clofazimine therapy.
    Mahapatra SB; Ramu G
    Lepr India; 1976 Apr; 48(2):172-6. PubMed ID: 1022964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphocyte transformation in lepromatous leprosy: a study of the influence of disease activity and symptom duration.
    Brown AE; Vithayasai V; Scollard DM; Nelson KE; Moses V; Schauf V; Makonkawkeyoon S
    Southeast Asian J Trop Med Public Health; 1986 Mar; 17(1):104-10. PubMed ID: 3738597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A component of Mycobacterium leprae as immunomodulating agent for immune deficient cells of leprosy patients.
    Robinson P; Mahadevan PR
    J Clin Lab Immunol; 1987 Dec; 24(4):171-6. PubMed ID: 3329228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural killer (NK) cell activity and reversal reaction in leprosy.
    Converse PJ; Bjune G
    Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):503-9. PubMed ID: 3819526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of leprosy.
    Katoch K
    Indian J Lepr; 1996; 68(4):349-61. PubMed ID: 9001903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. The effect of dapsone treatment on the response to Mycobacterium leprae antigens, tuberculin purified protein derivative and non-mycobacterial stimulants.
    Reitan LJ; Closs O; Belehu A
    Int J Lepr Other Mycobact Dis; 1982 Dec; 50(4):455-67. PubMed ID: 6763003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lepromin-induced suppressor cells in patients with leprosy.
    Mehra V; Mason LH; Fields JP; Bloom BR
    J Immunol; 1979 Oct; 123(4):1813-7. PubMed ID: 158056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A placebo controlled clinical trial of transfer factor in lepromatous leprosy.
    Faber WR; Leiker DL; Nengerman IM; Schellekens PT
    Clin Exp Immunol; 1979 Jan; 35(1):45-52. PubMed ID: 371887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphoproliferation and in vitro antibody synthesis in leprosy patients.
    Yandava CN; Bhutani LK; Sharma AK; Nath I
    Int J Lepr Other Mycobact Dis; 1989 Sep; 57(3):633-40. PubMed ID: 2674302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defect in the generation of cytotoxic T cells in lepromatous leprosy.
    Stach JL; Strobel M; Fumoux F; Bach JF
    Clin Exp Immunol; 1982 Jun; 48(3):633-40. PubMed ID: 6214342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocular complications in incident relapsed borderline lepromatous and lepromatous leprosy patients in south India.
    Daniel E; Koshy S; Joseph GA; Rao PS
    Indian J Ophthalmol; 2003 Jun; 51(2):155-9. PubMed ID: 12831146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal transplantation in leprosy patients.
    Roselino AM; de Almeida AM; Foss NT; Lima VJ; Raspanti EO; Ferraz AS
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):102-5. PubMed ID: 8326170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human leukocyte antigens in forms of leprosy among Japanese patients.
    Joko S; Numaga J; Kawashima H; Namisato M; Maeda H
    Int J Lepr Other Mycobact Dis; 2000 Mar; 68(1):49-56. PubMed ID: 10834069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
    Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
    Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.